CN102961358B - A kind of abiraterone acetate liquid capsule - Google Patents
A kind of abiraterone acetate liquid capsule Download PDFInfo
- Publication number
- CN102961358B CN102961358B CN201210497663.XA CN201210497663A CN102961358B CN 102961358 B CN102961358 B CN 102961358B CN 201210497663 A CN201210497663 A CN 201210497663A CN 102961358 B CN102961358 B CN 102961358B
- Authority
- CN
- China
- Prior art keywords
- capsule
- abiraterone acetate
- content
- acid
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a kind of abiraterone acetate liquid capsule, including capsule shells and content, the content includes Abiraterone acetate 8% 25%, oil phase 74.8 91.8%, account for the percentage by weight of content, wherein, oil phase includes mono fatty acid glyceride and solvent, and its weight ratio is 1：4‑4：1.The capsule of the present invention is free of surfactant, and dissolution rate is good, and safe, preparation technology is simple.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, and in particular to a kind of abiraterone acetate liquid capsule, and the capsule includes glue
Softgel shell and content, the content include Abiraterone acetate 8%-25%, oil phase 74.8-91.8%, account for the weight of content
Percentage, wherein, oil phase includes mono fatty acid glyceride and solvent, and its weight ratio is 1：4-4：1.Capsule produced by the present invention is not
Containing surfactant, dissolution rate is good, and safe, preparation technology is simple.
Background technology
Abiraterone acetate（abiraterone acetate）, it is chemical entitled：(3 β) -17- (3- pyridine radicals)-androstane -5,
16- dien-3-ols acetates, its chemical constitution is as follows.
Abiraterone acetate can be converted into abiraterone in vivo, and abiraterone is a kind of cytochrome pathways
(CYP450) c17 inhibitor, by suppress androgen synthesis in key enzyme --- CYP450c17 and reduce androgen levels,
Therefore, abiraterone not only also has inhibitory action to testis to the androgen of the generations such as other positions of body such as adrenal gland.
Growth of the androgen to prostate gland cancer cell has facilitation, at present, the general preferred bag of advanced prostate cancer patients
The castration method including medicine and operation is included to reduce testis synthetic androgen, but this treatment can not suppress body other
Position produces androgen.U.S. FDA, which ratifies Abiraterone acetate in April, 2011, is used for the treatment of advanced prostate cancer.Due to
Abiraterone acetate belongs to endocrine therapy, can suppress the androgen that testis and other positions of body are produced simultaneously, therefore relatively
In current conventional therapy, it has more preferable curative effect, and the frontier of anti-androgen therapy has been started in lower side effect.
Although Abiraterone acetate oral medication advanced prostate cancer works well, the physical characteristic of its dissolubility difference is given
Formulation development brings serious puzzlement, and listing preparation improves the active component using proper amount of surfactant is added in prescription
Dissolution rate, although facilitation is played in the dissolution to active component to a certain extent, but due to introducing surfactant
Also increase patient medication toxic side effect occurrence risk.The present inventor is by Abiraterone acetate and a certain amount of Capmul MCM C8
Iquid capsule is made jointly with the mixture of the sour fat of solvent such as medium chain triglyceride three, the dissolution speed of the active component is significantly improved
Rate, reduces toxic side effect occurrence risk, solves the important problem of puzzlement acetic acid Ah's bit formulation development.
Abiraterone acetate there is no to be prepared as the document report of iquid capsule at present.
The content of the invention
Object of the present invention is to provide a kind of abiraterone acetate liquid capsule, including described in capsule shells and content
Content includes Abiraterone acetate and oil phase, and the oil phase includes mono fatty acid glyceride and solvent, and the capsule is gelatin
Soft capsule or snap fit capsule.
In one embodiment, abiraterone acetate liquid capsule of the present invention, including capsule shells and content, institute
State content and include Abiraterone acetate 8%-25%, oil phase 74.8-91.8%, be the percentage by weight for accounting for content.
In the above-described embodiment, abiraterone acetate liquid capsule of the present invention, the oil phase includes monoester fat
Acid glyceride and solvent, wherein, the weight ratio of the mono fatty acid glyceride and solvent is 1：4-4：1, the solvent is selected from sweet
Fatty acid oil dibasic acid esters, the ester of glycerine fatty acid three, propane diols, PEG400 and their mixture, wherein, the aliphatic acid is selected from pungent
Acid, capric acid and its mixture, it is preferable that the solvent is median chain triglyceride oil, propane diols or PEG400.
Term：In the present invention, median chain triglyceride oil refers to the triglycerides of caprylic-capric acid mixing（It is i.e. commercially available medicinal auxiliary
Material）, also known as Glycerin, mixed triester with caprylic acid capric acid, the acid esters of medium chain fatty acid three, English name：Medium Chain Trglycerides, this
Strain is done something in disregard of obstacles the fat oil of extracting section, or the octanoic acid that the fat oil extracted by the dry endosperm of oil palm is isolated by the endosperm of coconut
（8 carbon atom saturated fatty acids）, capric acid（10 carbon atom saturated fatty acids）With glycerine esterification and triglyceride mixture.Monoester
Fatty acid glyceride is selected from Monooctamoin or monocaprin.Monooctamoin also known as sad monoglyceride, are octanoic acid
With glycerine through the obtained monoesters of catalysis；Monocaprin also known as capric acid monoglyceride, are that capric acid and glycerine are obtained through catalysis
Monoesters.
In the above-described embodiment, abiraterone acetate liquid capsule of the present invention, further comprising antioxidant, its
Weight is that antioxidant described in the 0.005%-0.2%. of content weight is butylated hydroxyarisol（BHA）, BHT
Or the two mixture (BHT).Preferably, the antioxidant is butylated hydroxyarisol（BHA）, BHT (BHT)
Or the two mixture.
In a preferred embodiment, abiraterone acetate liquid capsule of the present invention, including capsule shells and content
Thing, the content includes Abiraterone acetate 8%-25%, oil phase 74.8-91.8%, is the percentage by weight for accounting for content,
Wherein, the oil phase includes Capmul MCM C8 and solvent, wherein, the weight ratio of the Capmul MCM C8 and solvent is 1：4-
4：1, the solvent is median chain triglyceride oil（The triglycerides mixed such as caprylic-capric acid）, propane diols or PEG400.
In above-mentioned preferred embodiment, abiraterone acetate liquid capsule of the present invention, further comprising antioxygen
Agent, its weight is that antioxidant described in the 0.005%-0.2%. of content weight is butylated hydroxyarisol（BHA）, fourth hydroxyl
Toluene (BHT) or the two mixture.Preferably, the antioxidant is butylated hydroxyarisol（BHA）, BHT
Or the two mixture (BHT).
In a further preferred embodiment, abiraterone acetate liquid capsule of the present invention, including capsule shells and
Content, the content includes Abiraterone acetate 8%-25%, oil phase 74.8-91.8% and antioxidant 0.005%-0.2%,
To account for the percentage by weight of content, wherein, the oil phase includes Capmul MCM C8 and solvent, wherein, single octanoic acid is sweet
The weight ratio of grease and solvent is 1：4-4：1, the solvent is median chain triglyceride oil（The glycerine three mixed such as caprylic-capric acid
Ester）.
In above-mentioned more preferred, abiraterone acetate liquid capsule of the present invention, the antioxidant is
Butylated hydroxyarisol（BHA）, BHT (BHT) or the two mixture.
In above-mentioned all embodiments, abiraterone acetate liquid capsule of the present invention, the capsule shells are
Routine encapsulation known to ability and flexible glue capsule material, such as snap fit capsule or gelatin soft capsule can be purchased by commercial sources
Obtain or prepare.
A kind of method for preparing abiraterone acetate liquid capsule, this method includes：Abiraterone acetate, antioxidant is molten
Xie Yu is heated in the mixed liquor of 35-70 DEG C of Capmul MCM C8, median chain triglyceride oil, and embedding is in flexible glue after stirring
In capsule or hard shell capsules, abiraterone acetate liquid capsule is made.
The Abiraterone acetate pharmaceutical composition of the present invention has the following advantages that：
1st, it is remarkably improved Abiraterone acetate dissolution rate；
2nd, the generation of preparation toxic side effect can be reduced；
3rd, preparation technology is simple, stable and controllable for quality.
Brief description of the drawings
Fig. 1：The accumulation stripping curve figure of Abiraterone acetate soft capsule, hard shell capsules and tablet
Embodiment
Following examples are used to be explained further and understand the present invention, but do not limit the scope of the invention.
Embodiment 1
Prescription：
Abiraterone acetate 8g
Median chain triglyceride oil 18.4g
Capmul MCM C8 73.4g
BHT 0.005g
Preparation method：Weigh recipe quantity Abiraterone acetate, BHT be dissolved in be heated to 70 DEG C of Capmul MCM C8 with
In the mixed liquor of chain triglyceride, embedding is made Abiraterone acetate soft capsule, is made altogether in soft capsule after stirring
Soft capsule 64.
Embodiment 2
Prescription：
Abiraterone acetate 12.5g
Median chain triglyceride oil 43.65g
Capmul MCM C8 43.65g
BHT 0.2g
Preparation method：Weigh recipe quantity Abiraterone acetate, BHT be dissolved in be heated to 35 DEG C of Capmul MCM C8 with
In the mixed liquor of chain triglyceride, embedding is made Abiraterone acetate soft capsule, is made altogether in soft capsule after stirring
Soft capsule 100.
Embodiment 3
Prescription：
Abiraterone acetate 25g
Median chain triglyceride oil 60g
Capmul MCM C8 15g
BHT 0.01g
Preparation method：Weigh recipe quantity Abiraterone acetate, BHT be dissolved in be heated to 60 DEG C of Capmul MCM C8 with
In the mixed liquor of chain triglyceride, embedding is made Abiraterone acetate soft capsule, is made altogether in soft capsule after stirring
Soft capsule 200.
Embodiment 4
Prescription：
Abiraterone acetate 12.5g
Median chain triglyceride oil 43.75g
Capmul MCM C8 43.75g
BHA 0.01g
Preparation method：Weigh recipe quantity Abiraterone acetate, BHA be dissolved in be heated to 45 DEG C of Capmul MCM C8 with
In the mixed liquor of chain triglyceride, embedding is made Abiraterone acetate soft capsule, is made altogether in soft capsule after stirring
Soft capsule 100.
Embodiment 5
Prescription：
Abiraterone acetate 12.5g
Median chain triglyceride oil 43.65g
Capmul MCM C8 43.65g
BHA 0.2g
Preparation method：Weigh recipe quantity Abiraterone acetate, BHA be dissolved in be heated to 45 DEG C of Capmul MCM C8 with
In the mixed liquor of chain triglyceride, embedding is made Abiraterone acetate soft capsule, is made altogether in soft capsule after stirring
Soft capsule 100.
Embodiment 6
Prescription：
Abiraterone acetate 12.5g
Median chain triglyceride oil 43.65g
Capmul MCM C10 43.65g
BHA 0.2g
Preparation method：Weigh recipe quantity Abiraterone acetate, BHA be dissolved in be heated to 45 DEG C of Capmul MCM C10 with
In the mixed liquor of chain triglyceride, embedding is made Abiraterone acetate soft capsule, is made altogether in soft capsule after stirring
Soft capsule 100.
Embodiment 7
Prescription：
Abiraterone acetate 12.5g
Median chain triglyceride oil 49.98g
Capmul MCM C8 49.98g
BHT 0.025g
BHA 0.025g
Preparation method：Recipe quantity Abiraterone acetate, BHT and BHA mixing antioxidant is weighed to be dissolved in and be heated to 55 DEG C
In the mixed liquor of Capmul MCM C8 and median chain triglyceride oil, acetic acid Ah ratio is made in soft capsule in embedding after stirring
Special dragon soft capsule, is made soft capsule 100 altogether.
Embodiment 8
Prescription：
Abiraterone acetate 12.5g
Median chain triglyceride oil 43.65g
Capmul MCM C8 43.65g
BHT 0.2g
Preparation method：Weigh recipe quantity Abiraterone acetate, BHT be dissolved in be heated to 55 DEG C of Capmul MCM C8 with
In the mixed liquor of chain triglyceride, in hard shell capsules abiraterone acetate liquid capsule is made, altogether system in embedding after stirring
Obtain iquid capsule 100.
Embodiment 9
Prescription：
Abiraterone acetate 12.5g
1.2 propane diols 49.98g
Capmul MCM C8 49.98g
BHT 0.05
Preparation method：Weigh recipe quantity Abiraterone acetate, BHT be dissolved in be heated to 55 DEG C of Capmul MCM C8 with
In the mixed liquor of 1.2 propane diols, Abiraterone acetate soft capsule is made in soft capsule in embedding after stirring, and is made soft altogether
Capsule 100.
Embodiment 10
Prescription：
Abiraterone acetate 12.5g
PEG400 49.95g
Capmul MCM C8 49.95g
BHT 0.01g
Preparation method：Weigh recipe quantity Abiraterone acetate, BHT be dissolved in be heated to 60 DEG C of Capmul MCM C8 with
In PEG400 mixed liquor, Abiraterone acetate soft capsule is made in soft capsule in embedding after stirring, and soft capsule is made altogether
200.
Embodiment 11
Prescription：
Abiraterone acetate 12.5g
1.2 propane diols 49.98g
Capmul MCM C8 49.97g
BHT 0.05
Preparation method：Weigh recipe quantity Abiraterone acetate, BHT be dissolved in be heated to 55 DEG C of Capmul MCM C8 with
In the mixed liquor of 1.2 propane diols, embedding is made abiraterone acetate liquid capsule, is made altogether in hard shell capsules after stirring
Capsule 100.
Embodiment 12
Prescription：
Abiraterone acetate 25g
PEG400 15g
Capmul MCM C8 60g
BHT 0.01g
Preparation method：Weigh recipe quantity Abiraterone acetate, BHT be dissolved in be heated to 60 DEG C of Capmul MCM C8 with
In PEG400 mixed liquor, abiraterone acetate liquid capsule is made in hard shell capsules in embedding after stirring, and capsule is made altogether
200.
Embodiment 13
Prescription：
Abiraterone acetate 12.5g
The glyceride 49.98g of capric acid two
Capmul MCM C8 49.98g
BHT 0.05
Preparation method：Weigh recipe quantity Abiraterone acetate, BHT and be dissolved in and be heated to 55 DEG C of the glyceride of capric acid two and list
In the mixed liquor of glycerol caprylate, Abiraterone acetate soft capsule is made in soft capsule in embedding after stirring, and is made soft altogether
Capsule 100.
Comparing embodiment 1
Abiraterone acetate 12.5g
Capmul MCM C8 87.49g
BHT 0.01g
Preparation method：Weigh recipe quantity Abiraterone acetate, BHT and be dissolved in and be heated in 70 DEG C of Capmul MCM C8,
Abiraterone acetate soft capsule is made in soft capsule in embedding after stirring, and soft capsule 100 is made altogether.
Comparing embodiment 2
Abiraterone acetate 12.5g
Median chain triglyceride oil 87.49g
BHT 0.01g
Preparation method：Weigh recipe quantity Abiraterone acetate, BHT and be dissolved in and be heated in 45 DEG C of Capmul MCM C8,
Abiraterone acetate soft capsule is made in soft capsule in embedding after stirring, and soft capsule 100 is made altogether.
Comparing embodiment 3
Abiraterone acetate 12.5g
The glyceride 87.49g of capric acid two
BHT 0.01g
Preparation method：Recipe quantity Abiraterone acetate, BHT is weighed to be dissolved in the glyceride of capric acid two for being heated to 45 DEG C,
Abiraterone acetate soft capsule is made in soft capsule in embedding after stirring, and soft capsule 100 is made altogether.
The dissolution determination of embodiment 7
Determine the abiraterone acetate liquid capsule and comparing embodiment 1 of embodiment 1,2,3,6,8,9,10 and compare
The Abiraterone acetate soft capsule and listing Abiraterone acetate piece of embodiment 2（Trade name：Zytiga）Dissolved corrosion.
The sample accumulation dissolution rate of table 1（%）
| Sample point/min | Zytiga | Comparing embodiment 1 | Comparing embodiment 2 | Comparing embodiment 3 | Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 6 | Embodiment 8 | Embodiment 9 | Embodiment 10 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 10 | 42.24 | 2.41 | 0.12 | 1.32 | 85.48 | 87.38 | 49.56 | 74.21 | 90.13 | 97.31 | 97.79 |
| 15 | 64.51 | 4.51 | 0.22 | 2.17 | 92.86 | 94.87 | 74.85 | 87.32 | 95.26 | 96.56 | 97.73 |
| 30 | 89.27 | 7.48 | 1.08 | 3.27 | 99.22 | 95.14 | 90.72 | 92.12 | 96.14 | 97.54 | 98.71 |
| 45 | 91.74 | 12.26 | 2.27 | 7.18 | 99.76 | 97.45 | 97.54 | 99.46 | 97.42 | 98.73 | 99.82 |
| 60 | 93.77 | 20.12 | 3.56 | 14.77 | 99.13 | 100.08 | 99.54 | 99.78 | 97.79 | 98.91 | 102.03 |
Shown by the comparing result of table 1 and Fig. 1, abiraterone acetate liquid capsule of the invention（Embodiment 1,2,3,6,
8、9、10）Each sample point dissolution rate is superior to list Abiraterone acetate film 30min in the past（Trade name：Zytiga）And ratio
Compared with the preparation of embodiment 1,2, while from comparing embodiment, merely using Capmul MCM C8, the sour fat of medium chain triglyceride three, the last of the ten Heavenly stems
Sour two glyceride can not reach satisfied result of extraction.It was found from above-mentioned experimental result, Abiraterone acetate liquid of the invention
Body capsule can effectively improve the dissolution rate of Abiraterone acetate, and due to surfactant-free in prescription, so said preparation
Toxic side effect is significantly less than listing preparation.
Claims (9)
1. a kind of abiraterone acetate liquid capsule, including capsule shells and content, it is characterised in that：The content is by acetic acid
Abiraterone, solvent, mono fatty acid glyceride and antioxidant composition；The solvent is selected from：Glycerin fatty acid diester, glycerin fatty
Sour three esters, 1,2- propane diols and their mixture.
2. capsule as claimed in claim 1, it is characterised in that：The content is by Abiraterone acetate 8.0% ~ 25.0%, molten
Agent 18.4 ~ 60.0%, mono fatty acid glyceride 15.0 ~ 73.5% and antioxidant 0.005 ~ 0.2% are constituted, and account for the weight of content
Percentage.
3. capsule as claimed in claim 1 or 2, the weight ratio of the mono fatty acid glyceride and solvent is 1:4~4:1.
4. capsule as claimed in claim 3, the mono fatty acid is selected from octanoic acid and capric acid.
5. capsule as claimed in claim 1, the aliphatic acid is selected from octanoic acid, capric acid and their mixture.
6. capsule as claimed in claim 5, the mixture is median chain triglyceride oil.
7. capsule as claimed in claim 1, the antioxidant is butylated hydroxyarisol, BHT or the two is mixed
Compound.
8. capsule as claimed in claim 1, the capsule shells are snap fit capsule or gelatin soft capsule.
9. a kind of method for preparing abiraterone acetate liquid capsule as claimed in claim 1, this method includes：Acetic acid Ah ratio
Special dragon, antioxidant, which are dissolved in, is heated to 35-70 DEG C of Capmul MCM C8 or Capmul MCM C10 and selected from propane diols and middle chain
In the mixed liquor of the solvent of triglyceride, Abiraterone acetate is made in soft capsule or hard shell capsules in embedding after stirring
Iquid capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210497663.XA CN102961358B (en) | 2012-11-29 | 2012-11-29 | A kind of abiraterone acetate liquid capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210497663.XA CN102961358B (en) | 2012-11-29 | 2012-11-29 | A kind of abiraterone acetate liquid capsule |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102961358A CN102961358A (en) | 2013-03-13 |
| CN102961358B true CN102961358B (en) | 2017-08-04 |
Family
ID=47791978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210497663.XA Active CN102961358B (en) | 2012-11-29 | 2012-11-29 | A kind of abiraterone acetate liquid capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102961358B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI717629B (en) * | 2017-08-28 | 2021-02-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | Pharmaceutical composition of cyp17 inhibitor and preparation method |
| CN111481523B (en) * | 2019-01-25 | 2023-03-24 | 鲁南制药集团股份有限公司 | Soft capsule for treating prostatic cancer and preparation method thereof |
| CN109846826A (en) * | 2019-01-25 | 2019-06-07 | 湖南华腾制药有限公司 | Abiraterone acetate flexible lipidosome and preparation method thereof |
| CN110354094B (en) * | 2019-01-25 | 2020-07-31 | 鲁南制药集团股份有限公司 | CYP17 inhibitor soft capsule and preparation method thereof |
| CN111012745A (en) * | 2020-01-06 | 2020-04-17 | 深圳海王医药科技研究院有限公司 | Abiraterone oral emulsion and preparation method thereof |
| CN113133984A (en) * | 2020-01-20 | 2021-07-20 | 鲁南制药集团股份有限公司 | CYP17 inhibitor preparation |
| CN113750032B (en) * | 2020-06-01 | 2024-07-16 | 成都海博为药业有限公司 | Oral abiraterone pharmaceutical composition, preparation method and application thereof |
| CN114306236B (en) * | 2021-12-15 | 2022-10-21 | 湖南慧泽生物医药科技有限公司 | Self-microemulsion system for loading abiraterone acetate, composition and application |
| JP7320903B2 (en) | 2021-12-15 | 2023-08-04 | 湖南慧▲澤▼生物医▲薬▼科技有限公司 | Compositions and uses containing abiraterone acetate |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1709231A (en) * | 2005-07-04 | 2005-12-21 | 宛六一 | Tolterodine tartrate soft capsule and its preparing method |
| CN101007011A (en) * | 2007-02-13 | 2007-08-01 | 中国药科大学 | Ginsenoside Rh2 self-emulsifying composition and its preparation method |
| CN102058577A (en) * | 2008-08-06 | 2011-05-18 | 北京协和药厂 | Medicament compound adopting bicyclo-ethanol as active component and preparation thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101390851B (en) * | 2008-08-06 | 2011-03-30 | 北京协和药厂 | Double-cyclitol medicine composition containing surfactant and preparation method thereof |
-
2012
- 2012-11-29 CN CN201210497663.XA patent/CN102961358B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1709231A (en) * | 2005-07-04 | 2005-12-21 | 宛六一 | Tolterodine tartrate soft capsule and its preparing method |
| CN101007011A (en) * | 2007-02-13 | 2007-08-01 | 中国药科大学 | Ginsenoside Rh2 self-emulsifying composition and its preparation method |
| CN102058577A (en) * | 2008-08-06 | 2011-05-18 | 北京协和药厂 | Medicament compound adopting bicyclo-ethanol as active component and preparation thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102961358A (en) | 2013-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102961358B (en) | A kind of abiraterone acetate liquid capsule | |
| KR101460871B1 (en) | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same | |
| CN101668517B (en) | Comprise the oral controlled release compositions of vitamin D compounds and waxy carrier | |
| JP6153922B2 (en) | Synergistic compositions and methods | |
| CN107073127A (en) | The solid oral dosage form of lipophilic compound | |
| JP2010540554A5 (en) | ||
| CN106999440B (en) | Pharmaceutical composition for oral administration comprising taxane | |
| CA3207801A1 (en) | Oily suspensions of microparticulate isotretinoin with improved oral bioavailability | |
| US20170246184A1 (en) | Methods of treating testosterone deficiency | |
| CN102793664B (en) | Sodium aescinate micro-emulsification injection and preparation method thereof | |
| JP6043429B2 (en) | 2,2 ', 6,6'-Tetraisopropyl-4,4'-biphenol soft capsule preparation and method for producing the same | |
| CN105125489B (en) | Pharmaceutical composition comprising Debiopharm | |
| Saw et al. | Pharmacodynamics of fish oil: protective effects against prostate cancer in TRAMP mice fed with a high fat western diet | |
| CN106170285A (en) | Comprise the pharmaceutical composition of antifungal and steroid | |
| EP3174601A1 (en) | Oral pharmaceutical composition of isotretinoin | |
| CN110013467A (en) | A kind of solia particle and preparation method thereof and pharmaceutical composition containing it | |
| CN103908440A (en) | Polyene phosphatidylcholine capsule and preparation method thereof | |
| CN110354094A (en) | A kind of CYP17 inhibitor soft capsule and preparation method thereof | |
| CN106999428B (en) | Formulations for efficient tocotrienol delivery | |
| CN109394724A (en) | A kind of butylphthalide liquid hard capsule preparation and preparation method thereof | |
| CN102872002A (en) | Hydroxysafflor yellow A oil solution and preparation method and application thereof | |
| CN104546713B (en) | A kind of Pharmaceutical composition containing cucurbitacin and preparation method thereof | |
| CN104523590B (en) | A kind of Clevidipine butyrate fat emulsion injection | |
| CN108186600B (en) | Soft capsule for improving liver function and preparation method thereof | |
| CN106619560B (en) | Polyene phosphatidyl choline capsule and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |